● Recruiting

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Condition: Acute Myeloid Leukemia (AML) · Sponsor: University Hospital, Angers

PhasePhase 2/Phase 3

Planned participants3100

Who can joinAll sexes, 18 Years to 61 Years

Healthy volunteersNo

About this study

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC) conditioning, will also be evaluated. With an adaptative design, this clinical trial could test up to 3 novel AML agents of interest.

This description comes directly from the study's public registry record.

Talk to the study team

Mathilde Hunault, PD · MaHunault@chu-angers.fr

DRCI Promotion Interne · + 33 2 41 35 68 28 · EcPromotionInterne@chu-angers.intra

Always discuss trial participation with your own doctor first.

Locations (56)

CH Amiens Hôpital Sud	Amiens, France	Recruiting
CHU Angers	Angers, France	Recruiting
CH Victor Dupouy	Argenteuil, France	Recruiting
Centre Hospitalier de la Côte Basque	Bayonne, France	Recruiting
Hôpital Jean Minjoz	Besançon, France	Recruiting
CH Beziers	Béziers, France	Recruiting
Hôpital Avicenne	Bobigny, France	Recruiting
CH Bordeaux	Bordeaux, France	Recruiting
Hôpital du Dr Duchenne	Boulogne-sur-Mer, France	Recruiting
Hôpital Morvan	Brest, France	Recruiting
CH Caen	Caen, France	Recruiting
Clinique du parc	Castelnau-le-Lez, France	Withdrawn

+ 44 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02416388